Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Archive

Pages:

  • A Sitemap for LambLawOffice.com
  • About Our Firm
  • Alabama: Medical Records Copying Charges Law / Statute
  • Alaska: Medical Records Copying Charges Law / Statute
  • Archive
  • Arizona: Medical Records Copying Charges Law / Statute
  • Arkansas: Medical Records Copying Charges Law / Statute
  • Asbestos & Mesothelioma Overview
  • Asbestos Claims: How Do I Get Legal Compensation?
  • Attorney Profile: Thomas J. Lamb
  • Benzene Cancer Resources
  • Benzene Case Evaluation Form
  • Benzene Cases Overview
  • Benzene Exposure
  • Benzene Exposure and AML
  • Benzene Exposure and MDS
  • Benzene Exposure in Industries
  • Benzene-Containing Products
  • Benzene-Related Diseases
  • Benzene: Frequently Asked Questions
  • Blog
  • Breast Implant and Lymphoma: Resources
  • Breast Implant and Lymphoma: Summary of Information
  • Breast Implants and Lymphoma FAQs: About the Disease
  • Breast Implants and Lymphoma FAQs: Prognosis
  • Breast Implants and Lymphoma FAQs: Risk Factors
  • Breast Implants and Lymphoma FAQs: Symptoms
  • Breast Implants and Lymphoma FAQs: Treatment
  • Breast Implants and Lymphoma: FDA Information
  • Breast Implants and Lymphoma: Frequently Asked Questions
  • Breast Implants and Lymphoma: The Disease
  • Breast Implants Cancer Case Evaluation Form
  • Breast Implants Cases Overview
  • California: Medical Records Copying Charges Law / Statute
  • Camp Lejeune Cancer Case Evaluation Form
  • Camp Lejeune Cancer Claims and Legal Representation Information
  • Camp Lejeune Justice Act: Cases, Claims, and Lawsuits Overview
  • Camp Lejeune Lawsuit “Offset” Reduction to Legal Compensation: The Issue is If and How Much
  • Camp Lejeune Legal Advertisements and Town Hall Events in North Carolina, Around the Country
  • Camp Lejeune Parkinson’s Disease Case Evaluation Form
  • Camp Lejeune Parkinson’s Disease Cases and Legal Compensation
  • Case Evaluation Explanation
  • Case Evaluation Menu
  • Class Action vs. Individual Lawsuits
  • Clothing and Equipment with PFAS Causing Cancers in Firemen
  • Colorado: Medical Records Copying Charges Law / Statute
  • Connecticut: Medical Records Copying Charges Law / Statute
  • Contact Us
  • Current Drug Injury Litigations
  • Delaware: Medical Records Copying Charges Law / Statute
  • Directions to Our Office at Lumina Station
  • Disclaimer and Copyright Notices
  • District of Columbia: Medical Records Copying Charges Law / Statute
  • Drug Injury Cases Overview
  • ED Drugs (as well as BPH and PAH drugs)
  • FDA Safety Alert about Philips Recall of CPAP Machines, BiPAP Devices, and Ventilators
  • Florida: Medical Records Copying Charges Law / Statute
  • Frequently Asked Questions
  • General Case Evaluation Form
  • GenX Cancer Case Evaluation Form
  • GenX Cancers Overview
  • GenX Contamination of Fayetteville Well Water: Who is at Risk?
  • GenX Research Sources
  • Georgia: Medical Records Copying Charges Law / Statute
  • Hawaii: Medical Records Copying Charges Law / Statute
  • Heartburn and Acid Reflux Drugs
  • Hepatitis C Treatment Drugs – DAAs
  • How Payment for Our Legal Services Works
  • How to File a Benzene Workers Compensation Claim in NC
  • Idaho: Medical Records Copying Charges Law / Statute
  • Illinois: Medical Records Copying Charges Law / Statute
  • Incretin Mimetic Drugs
  • Indiana: Medical Records Copying Charges Law / Statute
  • Iowa: Medical Records Copying Charges Law / Statute
  • Kansas: Medical Records Copying Charges Law / Statute
  • Kentucky: Medical Records Copying Charges Law / Statute
  • Lamb Law Blog
  • Learn More About How We Work
  • Louisiana: Medical Records Copying Charges Law / Statute
  • Maine: Medical Records Copying Charges Law / Statute
  • Maryland: Medical Records Copying Charges Law / Statute
  • Massachusetts: Medical Records Copying Charges Law / Statute
  • Medical Records Copying Charges
  • Medical Records Costs Update 2020: 21st Century Cures Act Amends “Patient Rates” Aspect of HITECH
  • Mesothelioma and Asbestos Lawsuits
  • Mesothelioma, Asbestos, and Legal Compensation: Basic Facts
  • Michigan: Medical Records Copying Charges Law / Statute
  • Minnesota: Medical Records Copying Charges Law / Statute
  • Mississippi: Medical Records Copying Charges Law / Statute
  • Missouri: Medical Records Copying Charges Law / Statute
  • Montana: Medical Records Copying Charges Law / Statute
  • NC Workers Compensation Benzene Disease Claims Filing Deadline
  • Nebraska: Medical Records Copying Charges Law / Statute
  • Nevada: Medical Records Copying Charges Law / Statute
  • New Hampshire: Medical Records Copying Charges Law / Statute
  • New Jersey: Medical Records Copying Charges Law / Statute
  • New Mexico: Medical Records Copying Charges Law / Statute
  • New York: Medical Records Copying Charges Law / Statute
  • North Carolina: Medical Records Copying Charges Law / Statute
  • North Dakota: Medical Records Copying Charges Law / Statute
  • Ohio: Medical Records Copying Charges Law / Statute
  • Oklahoma: Medical Records Copying Charges Law / Statute
  • Oregon: Medical Records Copying Charges Law / Statute
  • Our Investigation of Your Case
  • Pennsylvania: Medical Records Copying Charges Law / Statute
  • Philips Breathing Devices Case Evaluation Form
  • Philips Breathing Devices Recall: Patient Injury Cases Overview
  • Philips CPAP Machines Recall: FDA Warning Issued in July 2021
  • Practice Areas
  • Quick Contact Form
  • Reporting Adverse Drug Reactions To The FDA MedWatch Program
  • Resources: Legal, Medical, and More
  • Rhode Island: Medical Records Copying Charges Law / Statute
  • September 2017: New GenX Information Soon to be Released
  • Sitemap for All Website Pages
  • South Carolina: Medical Records Copying Charges Law / Statute
  • South Dakota: Medical Records Copying Charges Law / Statute
  • Tennessee: Medical Records Copying Charges Law / Statute
  • Texas: Medical Records Copying Charges Law / Statute
  • Thank You For Allowing Us To Review Your Possible Case
  • Thank You for Completing Our Form
  • Thomas J. Lamb – Drug Injury, Asbestos Mesothelioma, Benzene Cancers
  • Timeline: GenX Contamination of the Cape Fear River
  • Timeline: GenX Study Results
  • Type 2 Diabetes Drugs (DPP-4 Inhibitors)
  • Type 2 Diabetes Drugs (SGLT-2 Inhibitors)
  • Utah: Medical Records Copying Charges Law / Statute
  • Vermont: Medical Records Copying Charges Law / Statute
  • Virginia: Medical Records Copying Charges Law / Statute
  • Washington: Medical Records Copying Charges Law / Statute
  • We Will Not Pressure or Rush You to Sign Our Contract of Representation
  • West Virginia: Medical Records Copying Charges Law / Statute
  • What are Mesothelioma, Asbestos Lung Cancer, and Asbestosis?
  • What is Asbestos?
  • What We Know About GenX
  • While We Are Working on Your Case
  • Wisconsin: Medical Records Copying Charges Law / Statute
  • Workers Who Could Be Exposed to Benzene
  • Wyoming: Medical Records Copying Charges Law / Statute
  • Your Drug Injury Case Review

Categories:

  • Asbestos
  • Benzene
  • Camp Lejeune
  • GenX
  • Mesothelioma
  • Uncategorized
  • Unsafe Drugs
  • Unsafe Medical Devices

Authors:

  • Legal Assistant (1)
  • Thomas Lamb (648)

Monthly:

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016

Recent Posts:

  • EPA Asks for More Public Input on Asbestos After ProPublica and Others Reveal New Information
  • Breast Implant-Associated Lymphoma: PROFILE Registry; Update on Number of Cases
  • A Gelatinous Pleural Effusion as a Diagnostic Clue
  • Firefighter Protective Gear Made With Toxic Chemicals PFAS
  • EzriCare and Delsam Products Recall: March 2023 Update
  • Delsam Pharma Artificial Eye Ointment Recall February 2023
  • Cancer patient asks court to end Georgia-Pacific asbestos bankruptcy
  • EzriCare and Delsam Pharma’s Eye Drops Products Recall
  • EzriCare Artificial Tears Eye Infections Warnings
  • Pleural Mesothelioma: A Rapid Evolution of an Indolent Disease
  • Avon Hit With $40 Million Verdict in California Talc Lawsuit
  • Valtrex Side Effect: DRESS Skin Reaction, Can be Fatal
  • Preoperative immunotherapy for mesothelioma shows favorable outcomes
  • Benzene Facts: Use, Science, Medical, and Legal
  • Tepezza Medical Articles About Drug Side Effects Focus on Hearing Issues
  • Asbestos — two to three times more deadly than known
  • Tepezza Hearing Loss, Other Tepezza Hearing Problems May be Irreversible and Permanent
  • They inhaled asbestos for decades on the job. Now, workers break their silence
  • FDA AdComm: Copiktra Risk-Benefit Profile No Longer Favorable as a Third-Line CLL/SLL Treatment
  • Malignant Mesothelioma Mortality in Women — United States, 1999–2020
  • Pembrolizumab / Lenvatinib Combo Shows Positive Clinical Activity in Recurrent Pleural Mesothelioma
  • Gallbladder Side Effects Related to Byetta and Other GLP-1 Receptor Agonists
  • The silent malignant mesothelioma epidemic: a call to action
  • Camp Lejeune Claims for Veterans and Family Diagnosed With Cancers
  • Breast Implants Lymphoma Cancer ALCL Case Numbers Increasing Rapidly in the US
  • Galinpepimut-S Plus Nivolumab Extends Survival in Malignant Pleural Mesothelioma
  • Second Surgery for Recurrent Malignant Pleural Mesothelioma after Multimodality Treatment: A Systematic Review
  • Copiktra May Increase Risks of Death and Serious Side Effects
  • A Case Report of Hypophosphatemia Leading to the Diagnosis of Mesothelioma
  • Xalkori Side Effects: Children Suffering Ocular Toxicity and Severe Visual Loss
  • Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly
  • Ukoniq Death Risk is Reason for Ukoniq Drug Recall Says FDA
  • Five PFAS Chemicals Added to List of Regional Screening and Removal Management Levels by the EPA
  • J&J, 2-stepping through talc litigation, faces fresh claims it hid workers’ asbestos exposure
  • Drug Injury Research: FDA Resources Online Available for Patients
  • CDC: Mesothelioma Deaths Up Among Women
  • Unexplained Pleural Effusion Leads to the Revelation of a Malignant Mesothelioma: A Case Report
  • Pericardial Mesothelioma Presenting as Constrictive Pericarditis
  • Ukoniq Withdrawn From Market Due to Increased Risk of Patient Deaths
  • Health Canada Breast Implant Safety Review Shows High Risk of BIA-ALCL with Textured Implants
  • Abemaciclib for Previously Treated Patients With p16ink4A-Deficient Mesothelioma
  • MS Drugs Ocrevus and Gilenya Linked to Melanoma, Other Skin Cancers
  • EPA rule would finally ban asbestos, carcinogen still in use
  • Fosamax Lawsuits Dismissed Again by March 2022 Preemption Ruling
  • April 2022 FDA Advisory Committee Meeting For Ukoniq Risk of Death
  • Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma
  • Biphasic Peritoneal Mesothelioma: A Lethal Clinical Entity
  • Beovu Label Change: Novartis Adds Information, Increases Safety Warnings in February 2022
  • How People Can Report Adverse Drug Reactions to the FDA MedWatch Program
  • An Overview of Benzene Exposure and its Adverse Health Effects
  • First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
  • Xeljanz, Rinvoq, and Olumiant Safety Review by European Drug Regulator EMA
  • Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
  • Possible Ukoniq Drug Recall Due to Increased Risk of Death
  • Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire
  • Xeljanz Safety Study Final Findings Presented in January 2022
  • Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire
  • Asbestos Exposure and Malignant Mesothelioma in Construction Workers
  • Beovu Drug Label Revised December 2021 Was Issued in Europe, But Not in the US
  • Xeljanz Safety Alert for People Who Are (1) Older, (2) Current / Past Smokers, or (3) With Cardiovascular or Cancer Risk Factors
  • EPA to Require Chemical Companies to Test Toxicity of Products
  • Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma
  • Immune Checkpoint Inhibitors Extend Survival for Mesothelioma
  • Elmiron-associated Retinopathy and Other Elmiron Eye Problem Side Effects
  • Beovu: Rates of Intraocular Inflammation and Retinal Vascular Occlusion
  • Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma
  • Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq
  • FDA Sets New Regulations for Breast Implant Manufacturers
  • Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  • Olumiant or Xeljanz: Is One of These JAK Inhibitor Drugs Safer?
  • Imfinzi-Chemo Combo Improves Survival for Mesothelioma
  • Certain Aerosol Antiperspirants Found to Contain High Levels of Benzene
  • Philips Ventilators Recall: What The Company Knew and When, What It Did or Did Not Do, and More FDA Findings Released November 2021
  • Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
  • Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma
  • GenX Contamination May Be More Toxic Than EPA Initially Thought
  • Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
  • Two Padcev-induced TEN / SJS Cases Where Patient Died From Their Padcev Side Effects
  • Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural Mesothelioma
  • Drug Regulator MHRA Imposes More Xeljanz Use Limitations in October 2021
  • Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
  • Imbruvica Heart-Related Side Effects and Cardiotoxicity Safety Issues
  • Access to care varies greatly among patients with malignant pleural mesothelioma
  • Possible New Xeljanz Side Effect: Peripheral Neuropathy
  • More Data in Support of Surgery for Malignant Pleural Mesothelioma
  • Appeals court reinstates suit by Solano County woman against Johnson & Johnson over baby powder
  • Padcev Linked to SJS and TEN: From No Warning to “Black Box” in Less Than 2 Years
  • Understanding the new therapeutic options for mesothelioma
  • Benzene Linked to Non-Hodgkin Lymphoma According to New Review of Past Studies
  • Elmiron and Maculopathy: Two Recent Medical Articles About an Elmiron Vision Side Effect
  • Xeljanz: Heart Attacks, Strokes, Cancers, Blood Clots, and Deaths – Updated FDA Warnings 2021
  • Surgery After Radiotherapy May Improve Outcomes in Patients with Malignant Pleural Mesothelioma
  • Tongue: the unusual site in malignant pleural mesothelioma
  • Tasigna Drug Injury Lawsuits Federal Court MDL Consolidation Order
  • Court upholds award to family of worker who died of asbestos exposure
  • Some Research Resources for Drug Safety and Warnings Information
  • Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma
  • Drug Injury Lawsuits: List of Some Cases Filed in First Half of 2021
  • Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma.
  • Johnson & Johnson Recalls Neutrogena and Aveeno Sunscreen Over Benzene Contamination Concerns

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.